Merrimack Justifies $11,200/Month For Onivyde In Pancreatic Cancer
Launch of Onivyde (MM-398) in metastatic pancreatic cancer will be rapid; Merrimack says market research suggests payers will be on board for labeled indication.
Launch of Onivyde (MM-398) in metastatic pancreatic cancer will be rapid; Merrimack says market research suggests payers will be on board for labeled indication.